Shopping Cart 0
Cart Subtotal
USD 0

EpiCast Report: Chronic Obstructive Pulmonary Disease-Epidemiology Forecasts to 2025

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3995

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 11985
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

EpiCast Report: Chronic Obstructive Pulmonary Disease-Epidemiology Forecasts to 2025

Summary

Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive lung disease (COLD), is a condition characterized by difficulty in breathing, shortness of breath, wheezing, chest tightness, and other respiratory symptoms that progress over time. The disease is often caused by tobacco smoking; however, long-term exposure to other lung irritants, such as smoke from vehicle emissions and power stations, chemical fumes, and dust from the environment and workplace, can also contribute to the development of COPD (NHLBI, 2013).

To forecast the total prevalent cases of COPD and the diagnosed prevalent cases of COPD in the 8MM, GlobalData epidemiologists used studies published in peer-reviewed journals that provided the age- and sex-specific total and diagnosed prevalent cases of COPD in the respective markets. The forecast methodology was consistent across the 8MM to allow for a meaningful comparison of the forecast numbers across the markets.

In the 8MM, GlobalData epidemiologists forecast that the total prevalent cases of COPD will increase from 65,991,432 cases in 2015 to 76,066,482 cases in 2025 at an Annual Growth Rate (AGR) of 1.53%. In the 8MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of COPD will increase from 24,482,101 cases in 2015 to 27,924,212 cases in 2025 at an AGR of 1.41%. The US had the highest number of total and diagnosed prevalent cases of COPD in the 8MM.

Scope

The Chronic obstructive pulmonary disease (COPD) EpiCast Report provides an overview of the risk factors and global trends of COPD in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast for the total prevalent cases of COPD (diagnosed and undiagnosed cases) and the diagnosed prevalent cases of COPD, which are segmented by sex and age (35-44, 45-54, 55-64, 65-74, and 75 years and older). The diagnosed prevalent cases of COPD are further segmented by the new GOLD 2011 severity stage (GOLD A, GOLD B, GOLD C, and GOLD D) using the COPD Assessment Test (CAT) scores and the modified Medical Research Council (mMRC) dyspnea scores.

The COPD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The COPD EpiCast report will allow you to

Develop business strategies by understanding the trends shaping and driving the global COPD market.

Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for COPD therapeutics in each of the markets covered.

Understand severity stages of COPD cases by CAT score and mMRC scores.

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Chronic Obstructive Pulmonary Disease: Executive Summary 4

2.1 Related Reports 6

3 Epidemiology 7

3.1 Disease Background 7

3.2 Risk Factors and Comorbidities 8

3.3 Global and Historical Trends 9

3.4 Forecast Methodology 11

3.4.1 Sources 13

3.4.2 Forecast Assumptions and Methods 15

3.4.3 Total Prevalent Cases 16

3.4.4 Diagnosed Prevalent Cases 18

3.4.5 Diagnosed Prevalent Cases of COPD by Severity 21

3.5 Epidemiological Forecast for COPD (2015-2025) 22

3.5.1 Total Prevalent Cases of COPD 22

3.5.2 Age-Specific Total Prevalent Cases of COPD 23

3.5.3 Sex-Specific Total Prevalent Cases of COPD 25

3.5.4 Diagnosed Prevalent Cases of COPD 26

3.5.5 Age-Specific Diagnosed Prevalent Cases of COPD 27

3.5.6 Sex-Specific Diagnosed Prevalent Cases of COPD 28

3.5.7 Diagnosed Prevalent Cases of COPD by Severity 29

3.6 Discussion 30

3.6.1 Epidemiological Forecast Insight 30

3.6.2 Limitations of Analysis 31

3.6.3 Strengths of Analysis 31

4 Appendix 32

4.1 Bibliography 32

4.2 About the Authors 35

4.2.1 Epidemiologist 35

4.2.2 Reviewers 35

4.2.3 Global Director of Therapy Analysis and Epidemiology 36

4.2.4 Global Head and EVP of Healthcare Operations and Strategy 36

4.3 About GlobalData 36

4.4 Contact Us 37

4.5 Disclaimer 37


List Of Figure

1.2 List of Figures

Figure 1: 8MM, Total Prevalent Cases of COPD, Both Sexes, Ages ?35 Years, 2015 and 2025 5

Figure 2: 8MM, Diagnosed Prevalent Cases of COPD, Both Sexes, Ages ?35 Years, 2015 and 2025 6

Figure 3: 8MM, Age-Standardized Total Prevalence of COPD (%), Ages ?35 Years, 2015 10

Figure 4: 8MM, Age-Standardized Diagnosed Prevalence of COPD (%), Ages ?35 Years, 2015 11

Figure 5: 8MM, Sources Used and Not Used to Forecast Total Prevalent Cases of COPD 13

Figure 6: 8MM, Sources Used and Not Used to Forecast Diagnosed Prevalent Cases of COPD 14

Figure 7: 8MM, Sources Used to Forecast the new GOLD 2011 Severity Stages Among the Diagnosed Prevalent Cases of COPD 15

Figure 8 : 8MM, Age-Specific Total Prevalent Cases of COPD, Both Sexes, N, 2015 24

Figure 9: 8MM, Sex-Specific Total Prevalent Cases of COPD, Both Sexes, N, 2015 25

Figure 10: 8MM, Age-Specific Diagnosed Prevalent Cases of COPD, Both Sexes, N, 2015 27

Figure 11: 8MM, Sex-Specific Diagnosed Prevalent Cases of COPD, Both Sexes, N, 2015 28

Figure 12: 8MM, Diagnosed Prevalent Cases of COPD by the GOLD Severity Stage (Using mMRC), Both Sexes, 2015 29

Figure 13: 8MM, Diagnosed Prevalent Cases of COPD by the GOLD Severity Stage (Using CAT), Both Sexes, 2015 30


List Of Table

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for COPD 9

Table 2: New GOLD 2011 Criteria for COPD Severity Stages 12

Table 3: 8MM, Total Prevalent Cases of COPD, Both Sexes, Ages ?35 Years, N, Selected Years 2015-2025 23

Table 4: 8MM, Age-Specific Total Prevalent Cases of COPD, Both Sexes, N, 2015. 24

Table 5: 8MM, Diagnosed Prevalent Cases of COPD, Both Sexes, Ages ?35 Years, N, Selected Years 2015-2025 26

Table 6: 8MM, Age-Specific Diagnosed Prevalent Cases of COPD, Both Sexes, N, 2015 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com